



Radiotherapy and Cancer

Guest Editor:

Dr. Andrew Hartley

Hall-Edwards Radiotherapy
Research Group, University
Hospital Birmingham NHS
Foundation Trust, Birmingham,
UK

andrew.hartley@uhb.nhs.uk

Deadline for manuscript
submissions:
closed (30 June 2019)

Message from the Guest Editor

Dear Colleagues,

Radiotherapy for cancer is rapidly evolving; the use of protons with the aim of sparing acute and late radiation toxicity and reducing second malignancies is becoming more widespread; interest in the potential use of other ions is increasing; stereotactic ablative body radiotherapy is being widely used as an alternative to surgery or to delay the initiation of palliative systemic chemotherapy; combinations of precision surgery and lower dose radiotherapy are being examined in randomized trials; immunotherapy is being tested in combination with radiotherapy; there is a renewed emphasis on both contour peer review and more detailed guidelines for clinical target volume definition. The purpose of this Special Issue is to examine these and other developments in radiotherapy.

Dr. Andrew Hartley
Guest Editor

